NIDDK Launches Phase III CellCept Study
The purpose of this study is to investigate the safety and effectiveness of a medication called CellCept in treating refractory (has not responded to other treatments) interstitial cystitis. Inotherwords, this is a study for patients who have more severe IC that have not responded to any therapies. In addition, they must have been diagnosed with a hydrodistention/cystoscopy.
CellCept is an immuno-suppressant. Immuno-suppressants work in the body by reducing the immune system’s ability to produce certain reactions that can cause inflammation. In some people, the inflammation produced by their immune system can damage healthy tissues and cause symptoms of pain and discomfort. CellCept is approved by the U.S. Food and Drug Administration (FDA) for use in patients who have had an organ transplant and helps to prevent the rejection of the transplanted organ.
The study will be conducted at eleven research centers throughout the USA & Canada.
For more info and a complete list of research centers, please visit:
The purpose of this study is to investigate the safety and effectiveness of a medication called CellCept in treating refractory (has not responded to other treatments) interstitial cystitis. Inotherwords, this is a study for patients who have more severe IC that have not responded to any therapies. In addition, they must have been diagnosed with a hydrodistention/cystoscopy.
CellCept is an immuno-suppressant. Immuno-suppressants work in the body by reducing the immune system’s ability to produce certain reactions that can cause inflammation. In some people, the inflammation produced by their immune system can damage healthy tissues and cause symptoms of pain and discomfort. CellCept is approved by the U.S. Food and Drug Administration (FDA) for use in patients who have had an organ transplant and helps to prevent the rejection of the transplanted organ.
The study will be conducted at eleven research centers throughout the USA & Canada.
For more info and a complete list of research centers, please visit:
Comment